Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases

APLAR Journal of Rheumatology

Volumn 7, Issue 1, 2004, Pages 44-48

  Yoon, Kam Hon ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b Block 102   (Singapore)

Author keywords

Lupus nephritis; Relapsed resistant disease; Tacrolimus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADULT; AGED; ANOREXIA; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASIA; CLINICAL ARTICLE; DIABETOGENESIS; DIARRHEA; DRUG EFFICACY; DRUG USE; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; RECURRENT DISEASE; RHEUMATIC DISEASE; RHEUMATOLOGY; SCLERODERMA; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 23644451673     PISSN: 02190494     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2004.00064.x     Document Type: Article

References (23)

1. Klintmalm GB (1999) Tacrolimus. In: LC Ginns, AB Cosimi, PJ Morris eds. Transplanatation Blackwell Science, Boston, 127-46.
2. Fuseler JW, Hearth-holmes M, Grisham MB et al. (2000) FK506 attenuates developing and established joint inflammation and suppresses interleukin 6 and nitric oxide expression in bacteria cell wall induced polyarthritis. J Rheumatol 27, 190-9.
3. Sakuma S, Nishigaki F, Magari K, Ogawa T, Miyata S, Ohkubo Y (2001) Fk506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm Res 50, 509-14.
4. Sakuma S, Kato Y, Nishigaki F et al. (2001) Effects of FK506 and other immunosuppressive anti-rheumatic agents on T-cell activation mediated IL-6 and IgM production invitro. Int Immunopharmacol 1, 749-57.
5. Migita K, Tanaka H, Okamoto K et al (2000) FK506 augments glucocorticoid-mediated cyclooxygenase-regulation in human rheumatoid synovial fibroblasts. Laboratory Invest 80, 135-41.
6. Takabayashi K, Koike T, Kurasawa K et al. (1989) Effect of FK506, a novel immunosuppressive drug on murine systemic lupus erythematosus. Clin Immunol Immunopathol 51, 110-7.
7. Entani C, Izumino K, Iida H et al. (1993) Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-Ipr/Ipr mice. Nephron 64, 471-5.
8. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T (2003) Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol 30, 2193-200.
9. Sharpiro R (2001) Tacrolimus. In: Sayegh MH, Remuzzi G eds. Current and future immunosuppressive therapies following transplantation Luwer Academic Publishers, Dordscehnt, 123-37.
10. Pham PT, Peng A, Wilkinson AH (2000) Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am I Kidney Dis 36, 844-50.
11. Gremillion RB, Posever Manek JO, West N, van Volen-Hoven JP (1999) Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. J Rheumatol 26, 2332-26.
12. Furst DE, Saag K, Fleischmann MR et al. (2002) Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate. Arthritis Rheum 46, 2020-8.
13. Kremer J, Habros J, Kolba K et al. (2002) Combination treatment with tacrolimus (Prograf; FK506) and methotrexate in rheumatoid arthritis patients who are partial responders to methotrexate. Arthritis Rheum 46, S1378.
14. Yocum D, Furst D, Kaine J et al. (2002) Efficacy and safety of tacrolimus (Prograf; FK506) in the treatment of rheumatoid arthritis (RA) in patients who have failed one or more DMARDs. Arthritis Rheum 46, S1381.
15. Yocum D, Furst D, Bensen W et al. (2002) Long term safety of tacrolimus (Prograf; FK506) in the treatment of rheumatoid arthritis (RA). Arthritis Rheum 46, S1444.
16. Duddridge M, Powell RJ (1997) Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56, 690-2.
17. Li SC, Kimura Y, Lieberman K, Ebner-Lyons L (2003) Teatment of pediatric patients with severe systemic lupus erythematosus with tacrolimus. Arthritis Rheum 48, S1287.
18. Wilkes M, Sereika S, Fertig N, Lucas M, Perez A, Oddis C (2003) Treatment of antisynthetase associated interstitial lung disease with tacrolimus in patients with idiopathic inflammatory myopathy. Arthritis Rheum 48, S1081.
19. Jegasothy BV, Ackerman CD, Todo S et al. (1992) Tacrolimus (FK506) - a new therapeutic agent for severe recalcitrant psoariasis. Arch Dermatol 128, 781-5.
20. Pilmore HL, Faire B, Ditter I (2001) Tacrolimus for the treatment of gout in renal transplantation: case reports and review of literature. Transplantation 72, 1073-5.
21. Kanekura T, Yoshii N, Terasaki K, Miyoshi H, Kanzaki T (2003) Efficacy of tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 148, 353-6.
22. Walker SL, Kirby B, Chalmers RJ (2002) The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 147, 405-6.
23. Nezondet-Chetaille AL, Nigrovic PA, Woodward AL et al. (2002) Efficacy of tacrolimus ointment for the treatment of cutaneous manifestations of juvenile dermatomyositis. Arthritis Rheum 46, S 768.